One year ago, the prospects for Portola’s anticoagulant Bevyxxa looked anything but certain. It had faltered in a phase 3 trial, forcing the company to reanalyze the data to make its case for FDA approval. It worked, but now Portola faces a challenging launch.
More: Investors cheered Portola's hard-won Bevyxxa nod. Could a takeover be next?